Beijing Meifuyuan Biotechnology

Beijing Meifuyuan Biotechnology is a Chinese biopharmaceutical company focused on the research and development of innovative drugs for metabolic and endocrine diseases. The company specializes in developing long-acting peptide therapeutics and small molecule inhibitors, with a particular emphasis on treatments for Type 2 diabetes and obesity. Meifuyuan maintains a robust pipeline that includes both generic improvements and novel chemical entities. Their operations encompass the full drug development lifecycle from early-stage discovery through clinical trials, aiming to provide high-quality, affordable therapeutic options for chronic conditions.